Mydecine Files Full Patent Application Covering MYCO-006 Family of Novel Short-Acting MDMA Analogs Jul 19, 2022
Mydecine’s Exclusive Dealer Identified as Licensed Psilocybin and MDMA Supplier in Canada Feb 8, 2022
Mydecine Submits Pre-Investigational New Drug Briefing Package to the FDA for MYCO-001 Seamless Phase 2/3 Smoking… Feb 1, 2022
Mydecine Signs LOI with The Newly Institute to Provide Psychedelic-Assisted Psychotherapy to Patients under Health… Jan 18, 2022
